Why is lctx dropping today

The stock price of LCTX decreased by 3.63% today. The decline in Lineage Cell Therapeutics Inc (LCTX) stock today can be attributed to **strategic partnership uncertainty**.

LCTX has recently formed a significant partnership with Roche/Genentech to advance its OpRegen cell therapy. While this partnership holds promise, especially with the positive long-term results from Phase 12A clinical trials and the durable treatment effect over three years, there are uncertainties surrounding the timing and outcome of ongoing clinical trials. Additionally, the company's reliance on non-dilutive funding strategies, such as grants and milestone payments, to reduce dependency on equity capital markets, could introduce financial constraints and raise concerns about the sustainability of its operations.

These factors, combined with the broader biotech market challenges, may have contributed to the decline in LCTX's stock price today.

|code|Ticker|Name|Date|Percentage Change|market_code|
|---|---|---|---|---|---|
|LCTX|LCTX.A|Lineage Cell|20250820|-3.225806451612906|170|

|code|Ticker|Name|Date|Pre-Market Percentage Change|market_code|
|---|---|---|---|---|---|
|LCTX|LCTX.A|Lineage Cell|20250820|2.314516129032254|170|